-
Vixarelimab: A Novel Approach to Targeting Prurigo Nodularis and Fibrosis(Post)
Quick Facts About VixarelimabWhat is Vixarelimab?Vixarelimab is an investigational monoclonal antibody developed to target oncostatin M receptor beta (OSMRβ), a key pathway involved in p
Tumor-Associated Macrophages: Double Agents in the Cancer Battlefield(Post)Tumor-Associated Macrophages: Double Agents in the Cancer Battlefield In the intricate theater of the human body, the immune system acts as a vigilant guardian, dispatching cellular soldiers to seek
Bridging ELISA sicher validieren: Praxisleitfaden für Antikörpernachweis(Post)Bridging ELISA sicher validieren: Praxisleitfaden für Antikörpernachweis Für den routinemäßigen Nachweis von Anti‑Drug‑Antikörpern ist das Bridging‑ELISA das gängigste Format, weil es isotypunabhängi
Plozalizumab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Info Section: Key Facts About PlozalizumabWhat is Plozalizumab?Plozalizumab is an investigational monoclonal antibody that targets CD47, a key immune checkpoint in cancer cells. By
Oligodendrocytes: Complete Guide + Functions & Development(Post)Oligodendrocytes are pivotal CNS cells, integral for myelin formation and nerve function, with implications in various neurological disorders. Key Takeaways Oligodendrocytes are specia
In Vivo Cell Depletion: Antibody Targets, Fc Mechanisms and Dosing(Post)A depletion experiment is only as good as the depletion you can prove. Injecting a functional-grade antibody and assuming the population is gone is the most common failure mode in in vivo immunology.
Fenofibrate Usage for Diabetes Damage(Post)Fenofibrate, also known as FEN, is a drug that is used to lower cholesterol levels. It works by blocking the absorption of dietary cholesterol in the small intestine and therefore, red
Praluzatamab: Unveiling the Promise of CD47-Targeted Therapy in Cancer Research(Post)Quick Facts About PraluzatamabWhat is Praluzatamab?Praluzatamab is an experimental monoclonal antibody that targets CD47, a “don’t eat me” signal used by cancer cells to evade immune des
Ferroptosis: A New Frontier in Cancer Therapy(Post)For decades, the primary strategy in cancer treatment has been to trigger apoptosis, a form of programmed cell death, in malignant cells. However, many cancers develop resistance to apoptosis-inducin
Epigenetic modifiication & Histone methylation(Post)Agata Miezaniec PhD Candidate, University of Nottingham, UK Epigenetics and the link to DNA Methylation The term ‘Epigenet
mRNA-1010 and Beyond: How Moderna's mRNA Platform is Revolutionizing Hantavirus Vaccine Development(Post)Hantavirus, a silent threat lurking in rodent populations, has long posed a significant public health challenge with its severe and often fatal outcomes. For decades, the quest for effective vaccines
Deprotonation: Unveiling the Chemistry Behind It(Post)Chemistry · Acid-BaseDeprotonation: Mechanism, pKa and Choosing the Right BaseDeprotonation is the removal of a proton from a molecule to give its conjugate base. Whether it happens, and how completel
10 reasons why you should do a science outreach event(Post)I'll start this post off with a story. When I was half way through my PhD and I had found my passion for science communication, I approached my supervisor for the first time to ask “Can I ha
Monalizumab: A Breakthrough in Cancer Immunotherapy Targeting NKG2A(Post)Quick Facts About MonalizumabWhat is Monalizumab?Monalizumab is a first-in-class immune checkpoint inhibitor targeting NKG2A, developed to enhance anti-tumor immune response by blocking
Galegenimab: Unlocking the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About GalegenimabWhat is Galegenimab?Galegenimab is an anti-CD47 monoclonal antibody designed to block the "don't eat me" signal, enhancing the immune system's ability to eli
Cancer & Tumour Suppressors – Mini Review(Post)Cancer DevelopmentCancer is a group of diseases that involves abnormal cell growth resulting in malignant tumours/ malignant neoplasms. Cancer is a leading cause of morbidity, with 14 million ne
Comment choisir protéine recombinante selon votre objectif expérimental(Post)Comment choisir protéine recombinante selon votre objectif expérimental Pour une protéine bactérienne non glycosylée destinée à un contrôle ELISA de routine, commencez par Escherichia coli : rendemen
TCA Cycle Assays(Page) The PD-1 Pathway and Cancer Immunotherapy(Post)The initial identification of PD-1 as a potential target for cancer treatment occurred in the late 1990s and early 2000s through studies exploring the regulation of T-cell responses.
ELISA 분석법, 원리, 프로토콜, 방법 및 키트(Page)